Oruka Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	2018 - 2014
Selling, General & Admin	8.47	6.28	5.85	5.5	4.77	3.98	Upgrade
Research & Development	0.66	1.01	4.75	13.83	4.99	1.83	Upgrade
Operating Expenses	9.13	7.3	10.6	19.34	9.77	5.81	Upgrade
Operating Income	-9.13	-7.3	-10.6	-19.34	-9.77	-5.81	Upgrade
Interest Expense / Income	0	0	0	0	0.01	0.01	Upgrade
Other Expense / Income	-1.93	-1.96	-0.67	-0.01	-0.03	-0.17	Upgrade
Pretax Income	-7.2	-5.34	-9.93	-19.32	-9.75	-5.65	Upgrade
Income Tax	0	0	0	0	-0.01	-0.17	Upgrade
Net Income	-7.2	-5.34	-9.93	-19.32	-9.74	-5.48	Upgrade
Shares Outstanding (Basic)	1	1	1	1	0	0	Upgrade
Shares Outstanding (Diluted)	1	1	1	1	0	0	Upgrade
Shares Change	0.67%	0.04%	3.64%	195.18%	256.50%	71.72%	Upgrade
EPS (Basic)	-6.00	-4.44	-8.28	-16.68	-24.84	-49.80	Upgrade
EPS (Diluted)	-6.00	-4.44	-8.28	-16.68	-24.84	-49.80	Upgrade
Free Cash Flow	-6.89	-5.01	-10.91	-18.81	-7.74	-4.81	Upgrade
Free Cash Flow Per Share	-5.70	-4.17	-9.09	-16.23	-19.73	-43.64	Upgrade
EBITDA	-7.12	-5.23	-9.81	-19.23	-9.65	-5.55	Upgrade
Depreciation & Amortization	0.08	0.11	0.11	0.09	0.09	0.09	Upgrade
EBIT	-7.2	-5.34	-9.93	-19.32	-9.74	-5.64	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).